TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29898753

Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS) and Long-Lasting Insecticide-Treated Bednets (LLINs) for malaria control
Number of subjects: 2936

Group type: COMPARATOR
Intervention: Historical data from 2005-2008 (Control)
Number of subjects: 2936
Study: 29898762

Group type: EXPERIMENTAL
Intervention: Pretreatment total hemoglobin (tHb)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cycle 1 %tHb
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cycle 2 %tHb
Number of subjects: 22

Group type: COMPARATOR
Intervention: HER2 subtype as a single predictor
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of tumor subtypes with tHb
Number of subjects: 22
Study: 29898763

Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation (NHFOV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 300
Study: 29898765

Group type: EXPERIMENTAL
Intervention: High-intensity interval walking training (3×30-minute sessions/week for 10 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-intensity interval walking training
Number of subjects: 12
Study: 29898822

Group type: EXPERIMENTAL
Intervention: High UA Z-score
Number of subjects: 8833

Group type: COMPARATOR
Intervention: Low UA Z-score
Number of subjects: 8833

Group type: COMPARATOR
Intervention: Normal UA Z-score
Number of subjects: 8833
Study: 29898843

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 0
Study: 29898901

Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitors (BGMs) tested in three studies; each BGM tested on average 115 subjects.
Number of subjects: 1035
Study: 29898959

Group type: EXPERIMENTAL
Intervention: STAT3 signaling disruption in myeloid cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mice with intact STAT3 signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STAT3-deficient macrophages
Number of subjects: 0

Group type: COMPARATOR
Intervention: IL-10 exposure in control BMDMs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STAT3 deficiency in BMDMs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coculture of IL-10-stimulated control BMDMs with fibroblasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STAT3 deficiency in BMDMs during coculture
Number of subjects: 0
Study: 29899062

Group type: EXPERIMENTAL
Intervention: Adoptive T-cell transfer therapy (ACT) targeting MART1 antigen
Number of subjects: 1
Study: 29899081

Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Roux-en-Y-gastric bypass (RYGB)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 61
Study: 29899212

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (once daily for 4 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Coadministration of tedizolid phosphate and pseudoephedrine (60 mg on day 5)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (once daily for 4 days)
Number of subjects: 18
Study: 29899763

Group type: EXPERIMENTAL
Intervention: PIPAC with oxaliplatin for colorectal PM and cisplatin/doxorubicin for other primary tumors
Number of subjects: 35
Study: 29899820

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) targeting BCMA using a fully human single chain variable fragment (scFv)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis of normal tissue expression using commercially available polyclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel, fully human scFv binding domains to BCMA generated by screening a naïve B-cell derived phage display library
Number of subjects: 0
Study: 29900143

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2700 mg/day EPA: DHA ratio=2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29901610

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 600
Study: 29901698

Group type: EXPERIMENTAL
Intervention: High EDIH scores (highest quintile)
Number of subjects: 120401
Study: 29901700

Group type: EXPERIMENTAL
Intervention: High-SFA diet (≥22 g/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-SFA diet (<22 g/d)
Number of subjects: 80
Study: 29901727

Group type: EXPERIMENTAL
Intervention: Overfeeding by 1250 kcal/d for 28 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High fat gainers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overfeeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insulin infusion at day 0
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin at day 28
Number of subjects: 40
Study: 29901782

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (Normal-weight, Overweight, Obese)
Number of subjects: 86
Study: 29902036

Group type: EXPERIMENTAL
Intervention: Service user co-facilitated antistigma and mhGAP trainings
Number of subjects: 17
Study: 29902097

Group type: EXPERIMENTAL
Intervention: Iron chelation therapy (ICT) using deferasirox
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron chelation therapy (ICT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29902683

Group type: EXPERIMENTAL
Intervention: 14 week supervised exercise-aided nicotine replacement therapy (NRT) cessation program
Number of subjects: 413
Study: 29902983

Group type: EXPERIMENTAL
Intervention: PRONTO training
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control (providers who did not attend training)
Number of subjects: 310
Study: 29902988

Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization after peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0
Study: 29903024

Group type: EXPERIMENTAL
Intervention: EQ-5D index
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: EQ-VAS score
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Income (< 2000 RMB)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Income (2000-4999 RMB)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Moderate or severe symptoms of discomfort (more than one symptom)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Hyperlipidemia
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Disease profile
Number of subjects: 997
Study: 29903707

Group type: EXPERIMENTAL
Intervention: Valproate at 60 mg/kg per day with R-CHOP
Number of subjects: 31

Group type: COMPARATOR
Intervention: R-CHOP (control group)
Number of subjects: 31
Study: 29903793

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg subcutaneously once monthly
Number of subjects: 1458
Study: 29903827

Group type: EXPERIMENTAL
Intervention: Sleep apnoea (measured by apnoea/hypopnoea index, AHI; mean±sd 15.9±11.5 events·h)
Number of subjects: 226
Study: 29903860

Group type: EXPERIMENTAL
Intervention: recombinant human angiotensin-converting enzyme 2 (rhACE2) at doses of 0.2 or 0.4 mg·kg
Number of subjects: 0
Study: 29905488

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 8 weeks
Number of subjects: 74
Study: 29905808

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg q24h
Number of subjects: 15

Group type: COMPARATOR
Intervention: darunavir/ritonavir 800/100 mg q24h
Number of subjects: 15
Study: 29906810

Group type: EXPERIMENTAL
Intervention: Endoscopic sutured gastroplasty using a novel suturing device
Number of subjects: 51

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 51
Study: 29907893

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 1612
Study: 29908078

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 73

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 73
Study: 29908231

Group type: EXPERIMENTAL
Intervention: Post-transplant bendamustine (PT-BEN)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Post-transplant cyclophosphamide (PT-CY)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Haploidentical bone marrow transplantation (haplo-BMT)
Number of subjects: 13
Study: 29908435

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study: 29908521

Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Rhinovirus
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Enterovirus
Number of subjects: 774

Group type: COMPARATOR
Intervention: RSVA
Number of subjects: 774

Group type: COMPARATOR
Intervention: RSVB
Number of subjects: 774

Group type: COMPARATOR
Intervention: Influenza A
Number of subjects: 774

Group type: COMPARATOR
Intervention: Influenza B
Number of subjects: 774

Group type: COMPARATOR
Intervention: Parainfluenza virus 1
Number of subjects: 774

Group type: COMPARATOR
Intervention: Parainfluenza virus 4
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Multiple virus detection
Number of subjects: 774
Study: 29908967

Group type: EXPERIMENTAL
Intervention: Clopidogrel (with aspirin)
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Higher platelet reactivity unit (PRU) levels
Number of subjects: 8582
Study: 29909069

Group type: EXPERIMENTAL
Intervention: 400 mg DSM265
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 250 mg DSM265
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 600 mg DSM265
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 800 mg DSM265
Number of subjects: 45
Study: 29909101

Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 8
Study: 29909109

Group type: EXPERIMENTAL
Intervention: Statin-taking patients (n = 781)
Number of subjects: 1255
Study: 29909549

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily for 12 weeks (HCV patients)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily for 14 days (healthy subjects)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily with ribavirin 1000 or 1200 mg divided twice daily (patients with compensated cirrhosis)
Number of subjects: 790
Study: 29909774

Group type: EXPERIMENTAL
Intervention: Maximal breath-hold during cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 17
Study: 29910040

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate)
Number of subjects: 389
Study: 29910050

Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor) for 6 months
Number of subjects: 0
Study: 29910127

Group type: EXPERIMENTAL
Intervention: Clinical-grade hPESC-derived midbrain dopaminergic (DA) neurons
Number of subjects: 0
Study: 29910190

Group type: EXPERIMENTAL
Intervention: Adipose lipid kinetics measurement
Number of subjects: 52
Study: 29910193

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 3560

Group type: COMPARATOR
Intervention: Antithrombotic therapy (antiplatelet therapy or anticoagulation)
Number of subjects: 3560
Study: 29910764

Group type: EXPERIMENTAL
Intervention: Ecological RAS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Artificial RAS
Number of subjects: 32
Study: 29911480

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) using the Shockwave Medical Peripheral IVL System
Number of subjects: 20
Study: 29911997

Group type: EXPERIMENTAL
Intervention: Passive infusion of the broadly neutralizing antibody VRC01 during analytical treatment interruption (ATI)
Number of subjects: 0
Study: 29912343

Group type: EXPERIMENTAL
Intervention: 3.7 GBq radioactive iodine (RAI) therapy
Number of subjects: 40
Study: 29912813

Group type: EXPERIMENTAL
Intervention: Microvesicles and micro-RNAs measurement
Number of subjects: 24
Study: 29912924

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 22
Study: 29912954

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted training for community health workers
Number of subjects: 572

Group type: COMPARATOR
Intervention: Paper-based training for community health workers (Control)
Number of subjects: 572
Study: 29913339

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Remifentanil (≥0.15 µg/kg/min)
Number of subjects: 57
Study: 29914446

Group type: EXPERIMENTAL
Intervention: Tailored intervention to enhance knowledge of, access to, and use of insurance and available services to reduce healthcare disparities.
Number of subjects: 0
Study: 29914509

Group type: EXPERIMENTAL
Intervention: Patient-reported fatigue severity (EORTC QLQ-C30)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) assessments using EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-INFO25
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 312
Study: 29914528

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 9
Study: 29914544

Group type: EXPERIMENTAL
Intervention: S1226 (8% CO2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29914560

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy with CT scans
Number of subjects: 993

Group type: COMPARATOR
Intervention: Absence of history of severe hemorrhage, dual antiplatelet therapy, headache or vomiting, and abnormal Glasgow coma scale score
Number of subjects: 993
Study: 29914796

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of a radioimmunotherapy agent targeting B7-H3 antigen, single infusion of 9.25 to 148 MBq at a concentration of about 37 MBq/mL.
Number of subjects: 28
Study: 29914867

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR) in symptomatic patients
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Baseline midwall late gadolinium enhancement (LGE) in asymptomatic patients
Number of subjects: 99

Group type: COMPARATOR
Intervention: Natural progression in asymptomatic patients
Number of subjects: 99
Study: 29914948

Group type: EXPERIMENTAL
Intervention: Amoxicillin treatment
Number of subjects: 21
Study: 29914960

Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethambutol (EMB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood samples collected predose and at 1, 2, 4, and 8 hours postdose.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bland-Altman plots
Number of subjects: 0
Study: 29915522

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 157
Study: 29915786

Group type: EXPERIMENTAL
Intervention: Combined use of tissue cultures and 16S rRNA gene polymerase chain reaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29915941

Group type: EXPERIMENTAL
Intervention: Reduced neutrophil CD88
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Reduced monocyte HLA-DR
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Elevated proportions of regulatory T cells (Tregs)
Number of subjects: 148
Study: 29916117

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) concomitantly with erlotinib
Number of subjects: 26
Study: 29916861

Group type: EXPERIMENTAL
Intervention: Continuous noninvasive blood pressure monitoring
Number of subjects: 316

Group type: COMPARATOR
Intervention: Intermittent blood pressure monitoring
Number of subjects: 316
Study: 29917066

Group type: EXPERIMENTAL
Intervention: Amplitude of low-frequency fluctuation (ALFF) in PD patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Amplitude of low-frequency fluctuation (ALFF) in healthy controls
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Regional homogeneity (ReHo) in PD patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Regional homogeneity (ReHo) in healthy controls
Number of subjects: 49
Study: 29917147

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) delivered house-to-house or at a central point, with or without compensation
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Knowledge about the rationale for MDA, asymptomatic infections, and transmission
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: MDA delivered house-to-house by volunteers at the end of the dry season
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: MDA targeted at individual villages or village clusters
Number of subjects: 163
Study: 29920516

Group type: EXPERIMENTAL
Intervention: Lifetime light alcohol drinkers (1-3 drinks per week)
Number of subjects: 99654

Group type: COMPARATOR
Intervention: Lifetime never or infrequent drinkers (<1 drink/week)
Number of subjects: 99654

Group type: EXPERIMENTAL
Intervention: Heavy drinkers (2-<3 drinks/day)
Number of subjects: 99654

Group type: EXPERIMENTAL
Intervention: Very heavy drinkers (3+ drinks/day)
Number of subjects: 99654
Study: 29920582

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) 200 mg at week 0, 100 mg at week 2, then 50 mg (<80 kg) or 100 mg (≥80 kg) every 4 weeks thereafter.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) with short-term mucosal healing (STMH) at week 14.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) after week 14 with STMH.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall cohort outcomes.
Number of subjects: 91
Study: 29920584

Group type: EXPERIMENTAL
Intervention: Southern participants
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Non-Southern participants
Number of subjects: 1227
Study: 29920885

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 29
Study: 29921512

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg per day for 4 weeks in repeated 6-week cycles until disease progression or prohibitive toxicity
Number of subjects: 30
Study: 29921523

Group type: EXPERIMENTAL
Intervention: Real-time biofeedback (RTBF) high-loading condition (5% vGRF increase)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Real-time biofeedback (RTBF) low-loading condition (5% vGRF decrease)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Real-time biofeedback (RTBF) symmetrical loading condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no RTBF)
Number of subjects: 30
Study: 29921557

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both surgical approaches
Number of subjects: 0
Study: 29921622

Group type: EXPERIMENTAL
Intervention: Ambulatory patch ECG recorder (Zio XT monitor) fitted in the ED, continuously records a single-lead ECG for up to 14 days.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Historical comparator group (no intervention mentioned).
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ambulatory patch ECG recorder (Zio XT monitor).
Number of subjects: 86
Study: 29921685

Group type: EXPERIMENTAL
Intervention: Combined optimisation of general anaesthesia involving goal-directed haemodynamic therapy (GDHT), lung-protective ventilation (LPV), and electroencephalographic depth of anaesthesia monitoring (DAM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined optimisation of general anaesthesia
Number of subjects: 27
Study: 29921736

Group type: EXPERIMENTAL
Intervention: 24-hour urine phosphorus measurement
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single 24-hour urine phosphorus measurement
Number of subjects: 8
Study: 29922050

Group type: EXPERIMENTAL
Intervention: Concurrent asthma diagnosis
Number of subjects: 19894

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 19894

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 19894
Study: 29922096

Group type: EXPERIMENTAL
Intervention: Estradiol valerate/dienogest (EV/DNG)
Number of subjects: 954
Study: 29922187

Group type: EXPERIMENTAL
Intervention: Information and Communication Technologies intervention
Number of subjects: 428
Study: 29922574

Group type: EXPERIMENTAL
Intervention: Volumetric biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FBA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical scores
Number of subjects: 0
Study: 29922676

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 112

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 112
Study: 29923063

Group type: EXPERIMENTAL
Intervention: Prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps during adjuvant docetaxel treatment
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Adjuvant docetaxel (cumulative dose ≥ 400 mg/m²)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Control group receiving only endocrine therapy
Number of subjects: 492
Study: 29923073

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PRP treatment
Number of subjects: 90
Study: 29923092

Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29923459

Group type: EXPERIMENTAL
Intervention: Stented DCB lesions
Number of subjects: 224
Study: 29923897

Group type: EXPERIMENTAL
Intervention: VCF group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Older adult group (NE)
Number of subjects: 39